Ridgelinediscovery

Ridgeline, a Versant Ventures Discovery Engine, creates and operates Versant-financed biotech companies. It works with entrepreneurs, industry and academic founders across Europe, the US and other regions to turn foundational science into new drug discovery companies.

The website describes its counterparties as entrepreneurs, academic founders and pharma industry partners rather than product buyers, and does not state a revenue model. It reports that companies it built, including Black Diamond Therapeutics, Bright Peak Therapeutics and Monte Rosa Therapeutics, now operate independently, and that Cimeio Therapeutics, Red Ridge Bio and SixPeaks Bio operate in collaboration with Ridgeline.

Founded in 2017, the company is registered as Ridgeline Discovery GmbH (legal name Ridgeline Therapeutics GmbH in structured data) with offices in Basel, Switzerland, at Aeschenvorstadt 36 and at the Technologiepark, Hochbergerstrasse 60 F. Open roles are in Basel and cover medicinal chemistry, DMPK, targeted protein degradation biology, medical direction and laboratory management. The website is in English.

Product: Venture-built drug discovery companies based on academic and industry science, developed and operated with Versant Ventures financing.